{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:15:56Z","timestamp":1787724956325,"version":"build-2784847793"},"reference-count":33,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,5,7]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>Some of the articles being published during the severe acute respiratory syndrome\u2013coronavirus (SARS-CoV)-2 pandemic highlight a link between severe forms of coronavirus disease 2019 (COVID-19) and the so-called cytokine storm, also with increased ferritin levels. However, this scenario is more complex than initially thought due to the heterogeneity of hyperinflammation. Some patients with coronavirus 2019 disease (COVID-19) develop a fully blown secondary haemophagocytic lymphohistiocytosis (sHLH), whereas others, despite a consistent release of pro-inflammatory cytokines, do not fulfil sHLH criteria but still show some features resembling the phenotype of the hyperferritinemic syndrome. Despite the final event (the cytokine storm) is shared by various conditions leading to sHLH, the aetiology, either infectious, autoimmune or neoplastic, accounts for the differences in the various phases of this process. Moreover, the evidence of a hyperinflammatory microenvironment provided the rationale to employ immunomodulating agents for therapeutic purposes in severe COVID-19. This viewpoint aims at discussing the pitfalls and issues to be considered with regard to the use of immunomodulating agents in COVID-19, such as timing of treatment based on the viral load and the extent of cytokine\/ferritin overexpression. Furthermore, it encompasses recent findings in the paediatric field about a novel multisystem inflammatory disease resembling toxic shock syndrome and atypical Kawasaki disease observed in children with proven SARS-CoV2 infection. Finally, it includes arguments in favour of adding COVID-19 to the spectrum of the recently defined \u2018hyperferritinemic syndrome\u2019, which already includes adult-onset Still\u2019s disease, macrophage activation syndrome, septic shock and catastrophic anti-phospholipid syndrome.<\/jats:p>","DOI":"10.1136\/rmdopen-2020-001295","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T10:18:05Z","timestamp":1589797085000},"page":"e001295","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":64,"title":["Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin"],"prefix":"10.1136","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1105-5640","authenticated-orcid":false,"given":"Alessia","family":"Alunno","sequence":"first","affiliation":[{"name":"Department of Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1958-5136","authenticated-orcid":false,"given":"Francesco","family":"Carubbi","sequence":"additional","affiliation":[{"name":"Department of Biotechnological and Applied Clinical Sciences, Rheumatology Unit, University of L\u2019Aquila, L\u2019Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0011-5102","authenticated-orcid":false,"given":"Javier","family":"Rodr\u00edguez-Carrio","sequence":"additional","affiliation":[{"name":"University of Oviedo, Instituto de Investigaci\u00f3n Sanitaria del Principado de Asturias, Oviedo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,5,18]]},"reference":[{"key":"2025090313020804000_6.1.e001295.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"2025090313020804000_6.1.e001295.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"2025090313020804000_6.1.e001295.3","doi-asserted-by":"crossref","unstructured":"Chenyang L , Shasha L , Liu Y . Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19. Ann Rheum Dis 2020. doi: 10.1136\/annrheumdis-2020-217460","DOI":"10.1136\/annrheumdis-2020-217460"},{"key":"2025090313020804000_6.1.e001295.4","doi-asserted-by":"crossref","unstructured":"Zhou Y , Fu B , Zheng X , et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv 2020. doi: 10.1101\/2020.02.12.945576","DOI":"10.1101\/2020.02.12.945576"},{"key":"2025090313020804000_6.1.e001295.5","doi-asserted-by":"crossref","unstructured":"Henderson LA , Canna SW , Schulert GS , et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol 2020. doi: 10.1002\/art.41285","DOI":"10.1002\/art.41285"},{"key":"2025090313020804000_6.1.e001295.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"2025090313020804000_6.1.e001295.7","doi-asserted-by":"crossref","unstructured":"McGonagle D , Sharif K , O\u2019Regan A , et al. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev 2020. doi: 10.1016\/j.autrev.2020.102537","DOI":"10.1016\/j.autrev.2020.102537"},{"key":"2025090313020804000_6.1.e001295.8","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S202015"},{"key":"2025090313020804000_6.1.e001295.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61048-X"},{"key":"2025090313020804000_6.1.e001295.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2018894618"},{"key":"2025090313020804000_6.1.e001295.11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.23812\/CONTI-E","article-title":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies","volume":"34","author":"Conti","year":"2020","journal-title":"J Biol Regul Homeost Agents"},{"key":"2025090313020804000_6.1.e001295.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13413-7"},{"key":"2025090313020804000_6.1.e001295.13","doi-asserted-by":"crossref","unstructured":"Henter JI , Horne A , Aric\u00f3 M , et al. HLH-2004:diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;124\u201331.","DOI":"10.1002\/pbc.21039"},{"key":"2025090313020804000_6.1.e001295.14","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025090313020804000_6.1.e001295.15","doi-asserted-by":"crossref","unstructured":"Ruan Q , Yang K , Wang W , et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020. doi: 10.1007\/s00134-020-05991-x","DOI":"10.1007\/s00134-020-05991-x"},{"key":"2025090313020804000_6.1.e001295.16","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-185"},{"key":"2025090313020804000_6.1.e001295.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.7507"},{"key":"2025090313020804000_6.1.e001295.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2007.11.003"},{"key":"2025090313020804000_6.1.e001295.19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/acr2.11048","article-title":"Ferritin to erythrocyte sedimentation rate ratio: simple measure to identify macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"1","author":"Eloseily","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"2025090313020804000_6.1.e001295.20","doi-asserted-by":"crossref","unstructured":"Sinha IP , Harwood R , Semple MG , et al. COVID-19 infection in children. Lancet Respir Med 2020. doi: 10.1016\/S2213-2600(20)30152-1","DOI":"10.1016\/S2213-2600(20)30152-1"},{"key":"2025090313020804000_6.1.e001295.21","unstructured":"Available https:\/\/picsociety.uk\/news\/pics-statement-regarding-novel-presentation-of-multi-system-inflammatory-disease\/"},{"key":"2025090313020804000_6.1.e001295.22","unstructured":"Available https:\/\/www.gaslini.org\/comunicati-stampa\/covid-19-nei-bambini-possibile-causa-del-notevole-incremento-dei-casi-di-malattia-di-kawasaki-riscontrati-nelle-ultime-settimane\/"},{"key":"2025090313020804000_6.1.e001295.23","unstructured":"Available https:\/\/wwwn.cdc.gov\/nndss\/conditions\/toxic-shock-syndrome-other-than-streptococcal\/case-definition\/2011\/"},{"key":"2025090313020804000_6.1.e001295.24","doi-asserted-by":"crossref","unstructured":"Menikou S , Langford PR , Levin M . Kawasaki disease: the role of immune complexes revisited. Front Immunol 2019. doi: 10.3389\/fimmu.2019.01156","DOI":"10.3389\/fimmu.2019.01156"},{"key":"2025090313020804000_6.1.e001295.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.07.007"},{"key":"2025090313020804000_6.1.e001295.26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/annrheumdis-2015-208982","article-title":"Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative","volume":"2016","author":"Ravelli","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025090313020804000_6.1.e001295.27","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1744483"},{"key":"2025090313020804000_6.1.e001295.28","doi-asserted-by":"crossref","unstructured":"Molloy EJ , Bearer CF . COVID-19 in children and altered inflammatory responses. Pediatr Res 2020. doi: 10.1038\/s41390-020-0881-y","DOI":"10.1038\/s41390-020-0881-y"},{"key":"2025090313020804000_6.1.e001295.29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3345\/cep.2020.00535","article-title":"Epidemiology and clinical features of coronavirus disease 2019 in children","volume":"63","author":"Choi","year":"2020","journal-title":"Clin Exp Pediatr"},{"key":"2025090313020804000_6.1.e001295.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2020.03.012"},{"key":"2025090313020804000_6.1.e001295.31","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/434560"},{"key":"2025090313020804000_6.1.e001295.32","unstructured":"Available https:\/\/www.aphp.fr\/contenu\/tocilizumab-improves-significantly-clinical-outcomes-patients-moderate-or-severe-covid-19"},{"key":"2025090313020804000_6.1.e001295.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30317-2"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:02:17Z","timestamp":1756929737000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,5,18]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/rmdopen-2020-001295"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001295","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}